Virbac SA

BATS-CHIXE:VIRPP Stock Report

Market Cap: €2.6b

Virbac Past Earnings Performance

Past criteria checks 5/6

Virbac has been growing earnings at an average annual rate of 14%, while the Pharmaceuticals industry saw earnings declining at 5.2% annually. Revenues have been growing at an average rate of 8.3% per year. Virbac's return on equity is 14.2%, and it has net margins of 10.5%.

Key information

14.0%

Earnings growth rate

14.1%

EPS growth rate

Pharmaceuticals Industry Growth14.1%
Revenue growth rate8.3%
Return on equity14.2%
Net Margin10.5%
Next Earnings Update14 Mar 2025

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Virbac makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

BATS-CHIXE:VIRPP Revenue, expenses and earnings (EUR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 241,3391416050
31 Mar 241,2931315890
31 Dec 231,2471215730
30 Sep 231,2291205700
30 Jun 231,2101195680
31 Mar 231,2131215630
31 Dec 221,2161225570
30 Sep 221,1841205350
30 Jun 221,1511195130
31 Mar 221,1071165000
31 Dec 211,0641134870
30 Sep 211,0251374730
30 Jun 219851614590
31 Mar 219601484490
31 Dec 209341364390
30 Sep 209441044440
30 Jun 20953724480
31 Mar 20946624510
31 Dec 19938524540
30 Sep 19921434490
30 Jun 19903344450
31 Mar 19886274460
31 Dec 18869204460
30 Sep 1886284420
30 Jun 18854-44380
31 Mar 18858-34400
31 Dec 17862-34420
30 Sep 17871164440
30 Jun 17879354460
31 Mar 17876354490
31 Dec 16872354520
30 Sep 16861304590
30 Jun 16850264660
31 Mar 16851184630
31 Dec 1585394600
30 Sep 15846214410
30 Jun 15839324210
31 Mar 15806483980
31 Dec 14773643750
30 Sep 14752603660
30 Jun 14730563570
31 Mar 14733583560
31 Dec 13736613550

Quality Earnings: VIRPP has high quality earnings.

Growing Profit Margin: VIRPP's current net profit margins (10.5%) are higher than last year (9.8%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: VIRPP's earnings have grown by 14% per year over the past 5 years.

Accelerating Growth: VIRPP's earnings growth over the past year (18.5%) exceeds its 5-year average (14% per year).

Earnings vs Industry: VIRPP earnings growth over the past year (18.5%) exceeded the Pharmaceuticals industry 9.5%.

Return on Equity

High ROE: VIRPP's Return on Equity (14.2%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/20 12:57
End of Day Share Price 2024/12/11 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Virbac SA is covered by 14 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Laurent GelebartBNP Paribas Exane
Carole RozenCA Cheuvreux
Arnaud CadartCIC Market Solutions (ESN)